Brief: Crescita Therapeutics Signs Pliaglis Out-Licensing Agreement With Cantabria Labs For €2.5M Upfront After Reacquiring Rest-Of-World Rights

Crescita Therapeutics

25/04/2019 14:23

April 25 (Reuters) - Crescita Therapeutics Inc  CTX.TO :
    * CRESCITA THERAPEUTICS SIGNS PLIAGLIS® OUT-LICENSING
AGREEMENT
WITH CANTABRIA LABS FOR €2.5M UPFRONT AFTER REACQUIRING
REST-OF-WORLD RIGHTS
    * CRESCITA THERAPEUTICS INC - CANTABRIA LABS WILL PAY
UPFRONT
PAYMENT OF EUR 2.5 MILLION
    * CRESCITA THERAPEUTICS - ENTERED COMMERCIALIZATION LICENSE
AGREEMENT WITH CANTABRIA LABS TO SELL, DISTRIBUTE PLIAGLIS IN
ITALY, PORTUGAL, FRANCE, SPAIN
    * CRESCITA THERAPEUTICS - IN ADDITION, CO AND CANTABRIA LABS
AGREED CANTABRIA LABS WILL TRANSFER MANUFACTURING OF PLIAGLIS TO
ITS NEW CENTRE
    * CRESCITA THERAPEUTICS INC - DURING A TRANSITION PERIOD,
GALDERMA
WILL CONTINUE TO DISTRIBUTE PLIAGLIS FOR ITALY AND BRAZIL
    * CRESCITA THERAPEUTICS INC - GALDERMA WILL ALSO MANUFACTURE
PRODUCT FOR ITALY, BRAZIL, CANADA AND MEXICO UNTIL OTHER
MANUFACTURING IS ARRANGED

Source text for Eikon:  ID:nCNWM4jbda 
Further company coverage:  CTX.TO 

 ((Reuters.Briefs@thomsonreuters.com;))